AMGN vs TGT Stock Comparison: Price, Growth & Valuation (2026)
Use MEXC Stock Compare for a detailed AMGN vs TGT analysis. Compare AMGN and TGT across price performance, growth, valuation, profitability and risk, based on market data and the latest reported financials.
AMGN vs TGT Stock Comparison Summary
AMGN reported year-over-year revenue growth of 9.1%, compared with 2.0% for TGT. Their P/E ratios are 25.1x and 16.2x, dividend yields are 2.41% and 2.91%, and 30-day volatility levels are 38.8% and 30.9%, respectively. These metrics highlight key differences in growth, valuation, dividend income and market risk. Overall TGT leads across more of the selected comparison metrics.
Risk Disclaimer: MEXC Stock Compare provides information and comparisons on actual U.S.-listed stocks for reference only. Data may be delayed or inaccurate, does not constitute investment advice, and past performance does not guarantee future results.
AMGN vs TGT Stock Return Comparison (1W)
Compare the cumulative total returns of Amgen Inc. (AMGN) and Target Corporation (TGT) over the selected 1W period. Data as of 2026-09-24 12:00:00.
AMGN vs TGT Key Equity Metrics Comparison Summary
Amgen Inc. (AMGN) has a market capitalization of $219.98B and operates in the Health Care sector, with its main business classified under Biotechnology. Its latest quarterly revenue changed +9.1% year over year.
Target Corporation (TGT) has a market capitalization of $71.25B and operates in the Consumer Staples sector, with its main business classified under Consumer Staples Merchandise Retail. Its latest quarterly revenue changed +2.0% year over year.
AMGN vs TGT Key Stock Indicators
| Comparison Metric | AMGN | TGT | Comparison results |
Stock Price & Returns Latest delayed stock price with 1-day, 1-month and year-to-date returns. | $406.901D: -0.4%1M: -8.0%1Y: +45.7% | $156.841D: +0.6%1M: -4.2%1Y: +77.6% | TGTWin |
Market Capitalization Total market value of the company's outstanding shares. | $219.98B | $71.25B | AMGNWin |
Sector & Industry The company's market sector and primary industry classification. | Health Care / Biotechnology | Consumer Staples / Consumer Staples Merchandise Retail | -- |
| Based on delayed market data, AMGN is trading at $406.90, compared with $156.84 for TGT. Their market capitalizations are $219.98B and $71.25B, respectively. AMGN operates in the Health Care sector, while TGT belongs to Consumer Staples. | |||
| AMGN vs TGT Growth & Profitability | |||
Revenue Growth (YoY) Year-over-year change in revenue. | +9.1% | +2.0% | AMGNWin |
EPS Growth (YoY) Year-over-year change in earnings per share. | +31.7% | +12.2% | AMGNWin |
ROIC Return generated from invested capital. | 16.7% | 17.5% | TGTWin |
Gross Margin / Operating Margin Profitability before and after operating expenses. | 69.5% / 30.0% | 29.3% / 5.6% | AMGNWin |
| On growth, AMGN posted revenue growth of +9.1% and TTM EPS growth of +31.7%. TGT, by comparison, posted revenue growth of +2.0% and TTM EPS growth of +12.2%.On profitability, AMGN recorded a gross margin of 69.5%, an operating margin of 30.0%, and ROIC of 16.7%. For TGT, the corresponding figures were 29.3%, 5.6%, and 17.5%.Overall, AMGN shows stronger overall growth and profitability. | |||
| AMGN vs TGT Valuation & Balance Sheet | |||
Free Cash Flow Yield Free cash flow as a percentage of market capitalization. | 4.6% | 6.3% | TGTWin |
Net Debt / EBITDA Net debt relative to EBITDA; a negative value indicates net cash. | 2.8x | 1.2x | TGTWin |
Dividend Yield / Payout Ratio Dividend returns relative to share price and the share of earnings paid as dividends. | 2.41% / 60.4% | 2.91% / 47.3% | TGTWin |
| TGT offers a higher free cash flow yield, indicating a less demanding valuation. TGT has the stronger balance sheet, while TGT provides the higher dividend yield. Overall, the two stocks differ mainly in valuation, financial strength and dividend income. | |||
| AMGN vs TGT Returns & Risk | |||
Total Return (Dividend-Adjusted) Cumulative return over 1, 5 and 10 years, including dividends. | 1Y: +45.7%5Y: +90.5%10Y: +134.5% | 1Y: +77.6%5Y: -35.0%10Y: +133.3% | AMGNWin |
30-Day Realized Volatility Annualized volatility based on the past 30 days of daily returns. | 38.8% | 30.9% | TGTWin |
Beta (5Y vs S&P 500) Sensitivity to market movements; above 1 indicates greater market volatility. | 0.43 | 0.94 | AMGNWin |
| AMGN has delivered stronger long-term returns, but the risk indicators show mixed results. | |||
AMGN vs TGT Valuation & Dividend Metrics
Review AMGN compared with TGT across valuation, cash flow and dividend metrics, including P/E, forward P/E, free cash flow yield and dividend yield. These figures are provided for reference only and do not represent a fair-value estimate, price target or investment recommendation.
| Metric | AMGN | TGT | Comparison results |
|---|---|---|---|
Market Cap | $219.98B | $71.25B | AMGNWin |
P/E (TTM) | 25.1x | 16.2x | TGTWin |
P/S | 5.8x | 0.7x | TGTWin |
EV/EBITDA | 16.3x | 8.8x | TGTWin |
Dividend Yield | 2.41% | 2.91% | TGTWin |
AMGN vs TGT Profitability Over Time
Compare AMGN and TGT across gross margin and operating margin trends over time to understand how each company's profitability has changed. Based on reported financial data only; not a forecast or investment advice.
| TTM | 3Y Avg | 5Y Avg | 10Y Avg | |
|---|---|---|---|---|
| AMGN | 67.2% | 66.3% | 69.9% | 75.4% |
| TGT | 28.1% | 27.1% | 27.8% | 28.6% |
Technical & Fundamental Stock Analysis
RSI (14, daily)
AMGN 52.45 • TGT 49.40
Measures short-term price momentum and helps identify possible overbought or oversold conditions.
50/200-DMA Position
AMGN 50D Above / 200D Above • TGT 50D Above / 200D Above
Shows whether the stock is trading above or below its medium- and long-term trend lines.
R&D % of Revenue
AMGN 20.0% • TGT 0.0%
Shows how much of revenue is invested in research and development.
Share Count Trend (3Y)
AMGN Stable • TGT Decreased
Shows whether the company's share count has increased or decreased over the past three years.
Company Profiles
Amgen Inc.
Biotechnology
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Target Corporation
Consumer Staples Merchandise Retail
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $104 billion in fiscal 2025 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2025 revenue), beauty and household essentials (30%), food and beverage (24%), hardlines (15%), as well as home furnishings (15%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
Trade AMGN & TGT Stock Futures on MEXC
Trade USDT-margined Stock Futures referencing AMGN and TGT on MEXC, with 24/7 access and leverage of up to 10x. These products are derivatives, do not represent ownership of the underlying shares and involve a significant risk of loss.
Everything You Need to Know About AMGN vs TGT Stocks
What is MEXC Stock Compare?
MEXC Stock Compare is a side-by-side US stock comparison tool. It helps users compare two companies across stock price performance, market cap, valuation, growth, profitability, balance-sheet strength, dividends and risk. The results are provided for research purposes only and do not constitute investment advice.
Which metrics should I use to evaluate a company's growth?
Start with revenue growth to see how quickly the business is expanding, then review EPS growth to determine whether that growth is translating into higher earnings per share. Gross margin, operating margin and ROIC help assess the quality of that growth by showing profitability and capital efficiency. A company with fast revenue growth but declining margins may be expanding without improving its earnings quality.
How do AMGN and TGT compare in growth and profitability?
In the latest reported period, AMGN recorded revenue growth of +9.1% and TTM EPS growth of +31.7%, compared with +2.0% and +12.2% for TGT. AMGN leads on both growth and profitability. This comparison is based on reported financial metrics and does not predict future performance.
What is the difference between P/E (TTM) and Forward P/E?
P/E (TTM) compares the current share price with actual earnings reported over the past 12 months. Forward P/E uses estimated earnings for the next 12 months, so it reflects market expectations but depends on forecasts that may change. Both ratios should be considered alongside growth, profitability and industry peers.
How do the risk profiles of AMGN and TGT compare?
AMGN has a 30-day realized volatility of 38.8% and a five-year Beta of 0.43, compared with 30.9% and 0.94 for TGT. The risk indicators show mixed results. These indicators describe historical price movements and market sensitivity, but they do not cover every source of investment risk.
What do dividend yield and payout ratio indicate?
Dividend yield shows the annual dividend relative to the current share price, while the payout ratio shows how much of a company's earnings is distributed as dividends. A higher yield may provide more income, but it can also rise because the share price has fallen. Dividend sustainability should therefore be considered together with earnings, cash flow and the payout ratio.
How should I compare a high-growth stock with a lower-valued stock?
A high-growth stock may trade at a higher valuation if investors expect its revenue and earnings to continue expanding. A lower-valued stock may offer a more conservative entry point, but the lower valuation could also reflect slower growth or higher business risk. Growth, valuation, profitability, cash flow and risk should therefore be considered together.
Which is the better stock, AMGN or TGT?
There is no single answer for every investor. Growth-focused investors may place greater weight on revenue growth, EPS growth and ROIC, while income-focused investors may prioritize dividend yield and payout sustainability. Investors with lower risk tolerance may focus more on volatility, Beta and balance-sheet strength. MEXC Stock Compare presents the relevant metrics but does not provide a buy or sell recommendation.
Can I trade AMGN and TGT as RealStocks on MEXC?
Eligible users can trade AMGN and TGT as real US stocks through MEXC RealStocks if both stocks are currently supported. Users must first open and verify a RealStocks account with MEXC's partner licensed broker. RealStocks represents ownership of actual shares rather than tokenized stock exposure. Availability may vary by stock and region, so users should check the corresponding RealStocks trading page before placing an order.
Disclaimer
The stock prices, financial metrics, comparison results and related information displayed on this page are sourced from third-party providers and are provided for informational and educational purposes only. Data may be delayed, incomplete or inaccurate, and MEXC does not guarantee its accuracy, completeness or timeliness. The comparisons and automated summaries do not constitute financial, investment, legal or tax advice, nor a recommendation to buy, sell or hold any security or financial product. Past performance is not indicative of future results. Users should independently verify the information and assess their own objectives, financial circumstances and risk tolerance before making any decision. Where MEXC stock futures or other derivative products are referenced, such products do not represent ownership of the underlying shares and may involve leverage and a substantial risk of loss. Product availability is subject to applicable laws and regional restrictions.